Aratana Therapeutics Inc. (NASDAQ:PETX) – Lake Street Capital boosted their FY2016 earnings per share estimates for shares of Aratana Therapeutics in a note issued to investors on Monday. Lake Street Capital analyst B. Jackson now anticipates that the brokerage will post earnings of ($0.71) per share for the year, up from their prior estimate of ($0.82). Lake Street Capital has a “Buy” rating and a $15.00 price target on the stock. Lake Street Capital also issued estimates for Aratana Therapeutics’ Q4 2016 earnings at ($0.41) EPS, Q1 2017 earnings at ($0.35) EPS, FY2018 earnings at ($0.46) EPS and FY2019 earnings at $0.22 EPS.

A number of other analysts have also recently commented on the company. Zacks Investment Research upgraded Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research report on Wednesday, July 20th. Jefferies Group assumed coverage on Aratana Therapeutics in a research report on Friday, August 19th. They issued a “buy” rating and a $13.00 price target on the stock. William Blair restated an “outperform” rating on shares of Aratana Therapeutics in a research report on Wednesday, August 17th. Barclays PLC dropped their price target on Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating on the stock in a research report on Thursday, August 11th. Finally, Credit Suisse Group AG restated a “buy” rating and issued a $11.00 price target on shares of Aratana Therapeutics in a research report on Wednesday, August 10th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $11.00.

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ:PETX) opened at 7.62 on Wednesday. The firm’s market cap is $267.40 million. Aratana Therapeutics has a one year low of $2.56 and a one year high of $10.73. The firm’s 50 day moving average price is $8.81 and its 200-day moving average price is $7.73.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.10. Aratana Therapeutics had a negative return on equity of 19.87% and a negative net margin of 60.32%. During the same quarter in the previous year, the company earned ($1.58) earnings per share.

Large investors have recently made changes to their positions in the stock. BlackRock Institutional Trust Company N.A. raised its stake in shares of Aratana Therapeutics by 14.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 869,516 shares of the biopharmaceutical company’s stock worth $5,495,000 after buying an additional 109,243 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Aratana Therapeutics by 8.1% in the second quarter. BlackRock Fund Advisors now owns 1,308,679 shares of the biopharmaceutical company’s stock valued at $8,271,000 after buying an additional 98,007 shares during the period. BlackRock Investment Management LLC raised its stake in shares of Aratana Therapeutics by 15.9% in the second quarter. BlackRock Investment Management LLC now owns 125,058 shares of the biopharmaceutical company’s stock valued at $790,000 after buying an additional 17,157 shares during the period. BlackRock Advisors LLC raised its stake in shares of Aratana Therapeutics by 3.6% in the second quarter. BlackRock Advisors LLC now owns 15,915 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 547 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Aratana Therapeutics by 20.4% in the second quarter. Vanguard Group Inc. now owns 1,270,655 shares of the biopharmaceutical company’s stock valued at $8,031,000 after buying an additional 214,900 shares during the period. 88.77% of the stock is currently owned by institutional investors.

In other Aratana Therapeutics news, insider Craig A. Tooman sold 30,000 shares of Aratana Therapeutics stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $9.25, for a total value of $277,500.00. Following the sale, the insider now owns 72,424 shares of the company’s stock, valued at approximately $669,922. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ernst Heinen sold 10,000 shares of Aratana Therapeutics stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $10.00, for a total value of $100,000.00. Following the completion of the sale, the insider now directly owns 115,494 shares in the company, valued at approximately $1,154,940. The disclosure for this sale can be found here. 6.70% of the stock is owned by company insiders.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

5 Day Chart for NASDAQ:PETX

Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.